Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 10Terminated 3Unknown 1Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 2NIH 1

Study Type

Observational 2Interventional 1

Sponsor

Cancer Type

Gynecologic 2

Conditions

Neoplasms 474Carcinoma, Non-Small-Cell Lung 449Breast Neoplasms 331Neoplasm Metastasis 243Colorectal Neoplasms 214Melanoma 213Leukemia, Myeloid, Acute 191Multiple Myeloma 180Recurrence 169Ovarian Neoplasms 169Prostatic Neoplasms 163Lymphoma, Non-Hodgkin 149Lung Neoplasms 134Pancreatic Neoplasms 125Lymphoma 124Carcinoma, Renal Cell 112Leukemia, Lymphocytic, Chronic, B-Cell 111Squamous Cell Carcinoma of Head and Neck 110Stomach Neoplasms 92Carcinoma, Hepatocellular 89Lymphoma, Large B-Cell, Diffuse 88Leukemia 88Triple Negative Breast Neoplasms 86Lymphoma, Follicular 82Head and Neck Neoplasms 79Glioblastoma 75Myelodysplastic Syndromes 70Urinary Bladder Neoplasms 68Small Cell Lung Carcinoma 64Precursor Cell Lymphoblastic Leukemia-Lymphoma 55

Interventions

ZD4054 1Paclitaxel 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × INDUSTRY × Hypersensitivity × Clear all
NCT00288275 2012-10-05

Correlation of the Chemoresponse Assay With PFS in Patients With Recurrent Epithelial Ovarian, Peritoneal, or Fallopian Tube Cancer

Precision Therapeutics

Terminated
256 enrolled
Gynecologic

Fallopian Tube Neoplasms, Hypersensitivity, Ovarian Neoplasms, Peritoneal Neoplasms, Recurrence

NCT00669422 2012-10-05

ChemoFx® PRO - A Post-Market Data Collection Study

Precision Therapeutics

Terminated
2,756 enrolled
Gynecologic

Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Hypersensitivity, Ovarian Neoplasms, Recurrence, Uterine Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms

NCT00929162 2012-08-07

ZD4054 (Zibotentan) or Placebo Plus Chemotherapy in Patients With Advanced Ovarian Cancer

AstraZeneca

Phase 2 Terminated
120 enrolled 8 charts

Hypersensitivity, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡